PPT-CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

IntroductionOverview Lowering HbA1c Reduces the Risk of Microvascular Complications But What About Macrovascular Complications December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM . Teaser. Zak Fallows. 2013-07-03. http://datb.mit.edu. pharmacology@mit.edu. 1. How the Brain Works. You have about 100 billion brain cells, which are called neurons.. Each neuron has about 1,000 connections, called synapses. (This number is extremely variable.). Dr. Neil Munro, . Esher. , . United Kingdom. Socio-economic consequences of major hypoglycaemia in T1D and T2D. T1D: 1.1–3.2 major hypoglycaemic events/year. 1. T2D: 0.1–0.7 severe hypoglycaemic events/year (treatment dependent). A lifetime risk challenge. Priorities in the management . of . type 2 diabetes:. Past, present and future. Sir George Alberti, MD. Diabetes UK Chairman. Newcastle. , United Kingdom. Cardio. Diabetes . A lifetime risk challenge. Priorities in the management . of . type 2 diabetes:. Past, present and future. Sir George Alberti, MD. Diabetes UK Chairman. Newcastle. , United Kingdom. Cardio. Diabetes . 24. th. November 2016. Andrew Gallagher. Consultant Physician. and Endocrinologist. NHS Greater Glasgow & Clyde. Prevalence – 2015 data. WORLDWIDE. . Almost 300 million people with diabetes aged 20-79. 1. AACE Comprehensive Diabetes Care: Glucose Goals . Parameter. Treatment Goal for . Nonpregnant. Adults. A1C (%). . Individualize based on age, comorbidities, and duration of disease*. ≤6.5 for most. 1. Obesity. Management of Common Comorbidities in Diabetes. 2. 3. 4. More Than Two Thirds of US Adults Are Overweight or Obese. 5. *2014 rate of overweight not reported in . Flegal. et al 2016; 2012 rate carried over based on historic stability of overweight prevalence.. Aspirin in Primary Prevention, GLP-1 Agonists, Metformin, Psychotropic Drug Monitoring. Nathan Bertsch, PharmD. Mitchell Elting, MD. Most patients should not take aspirin for primary prevention of cardiovascular disease. Antidiabetes. Medications:. Cardiovascular Benefits. Hengameh. . Abdi. Endocrine Research Center. Research Institute for Endocrine sciences. Shahid. . Beheshti. University of Medical Sciences. 13 December 2018. Prof Kausik Ray, . BSc (. hons. ), . MBChB. , MRCP, MD, MPhil (. Cantab. ), FACC, FESC, FAHA. Professor of Cardiovascular Disease Prevention. St Georges University of London. Honorary Consultant Cardiologist St Georges Hospital. David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . Lispro 5-15 Hrs 1-2 4-5 NPH 1-2 Hrs 5-7 13-18 Lente 1-3 Hrs 4-8 13-20 Ultralente 2-4 Hrs 8-10 18-30 INT. J. DIAB. DEV. COUNTRIES (2000), VOL. 20 oxidation are also reduced by metformin. Metformin for HCSWs. Katharine Ramage. Diabetes MCN Professional Education Lead/DSN. Learning Outcomes. Develop an understanding of the different types of diabetes, risk factors for developing diabetes, how it can present and how it is diagnosed. Major Metabolic Defects in Type 2 Diabetes . Physiopathology of diabetes includes multiple metabolic . defects:1-4. . Progressive β-cell failure/decreased insulin secretion . Insulin resistance . α-.